|
12 Jul 2019 |
GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule
|
|
11 Jul 2019 |
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
|
|
08 Jul 2019 |
Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
|
|
08 Jul 2019 |
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
|
|
08 Jul 2019 |
Casebia Highlights Novel Research in Gene Editing Therapeutics for Hemophilia A
|
|
08 Jul 2019 |
Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02
|
|
08 Jul 2019 |
Celyad Presents Update on Autologous & Allogeneic NKG2D-based CAR-T Therapies in Solid Tumors
|
|
06 Jul 2019 |
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
|
|
06 Jul 2019 |
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
|
|
04 Jul 2019 |
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
|
|
03 Jul 2019 |
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
|
|
01 Jul 2019 |
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria
|
|
01 Jul 2019 |
Semma Therapeutics Announces Pre-Clinical Proof-of-Concept in Two Lead Programs in Type 1 Diabetes
|
|
01 Jul 2019 |
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
|
|
01 Jul 2019 |
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)
|
|
28 Jun 2019 |
Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma
|
|
28 Jun 2019 |
Alexion Receives FDA Approval of SOLIRIS® (eculizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 (AQP4) Antibody Positive
|
|
27 Jun 2019 |
Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis
|
|
27 Jun 2019 |
Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
|
|
27 Jun 2019 |
Translate Bio Announces FDA Clearance to Proceed with a Single-ascending Dose (SAD) Phase 1/2 Clinical Trial for Ornithine Transcarbamylase (OTC) Deficiency
|
|
27 Jun 2019 |
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
|
|
25 Jun 2019 |
TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab
|
|
24 Jun 2019 |
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
|
|
24 Jun 2019 |
Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer
|
|
24 Jun 2019 |
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103
|
